Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets

Around 3–7% of patients with non-small cell lung cancer (NSCLC) have a translocation in the gene for anaplastic lymphoma kinase (ALK) (1). Since the first report of ALK detection in NSCLC in 2007, the prognosis and the treatment landscape has been revolutionized for this setting of patients (2).